Targeting Casein Kinase 1 (CK1) in Hematological Cancers
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F20%3A00540072" target="_blank" >RIV/68081707:_____/20:00540072 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/1422-0067/21/23/9026" target="_blank" >https://www.mdpi.com/1422-0067/21/23/9026</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms21239026" target="_blank" >10.3390/ijms21239026</a>
Alternative languages
Result language
angličtina
Original language name
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
Original language description
The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven CK1 isoforms identified in humans. The most important substrates of CK1 kinases are proteins that act in the regulatory nodes essential for tumorigenesis of hematological malignancies. Among those, the most important are the functions of CK1s in the regulation of Wnt pathways, cell proliferation, apoptosis and autophagy. In this review we summarize the recent developments in the understanding of biology and therapeutic potential of the inhibition of CK1 isoforms in the pathogenesis of chronic lymphocytic leukemia (CLL), other non-Hodgkin lymphomas (NHL), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and multiple myeloma (MM). CK1 delta/epsilon inhibitors block CLL development in preclinical models via inhibition of WNT-5A/ROR1-driven non-canonical Wnt pathway. While no selective CK1 inhibitors have reached clinical stage to date, one dual PI3K delta and CK1 epsilon inhibitor, umbralisib, is currently in clinical trials for CLL and NHL patients. In MDS, AML and MM, inhibition of CK1 alpha, acting via activation of p53 pathway, showed promising preclinical activities and the first CK1 alpha inhibitor has now entered the clinical trials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Molecular Sciences
ISSN
1422-0067
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
23
Country of publishing house
CH - SWITZERLAND
Number of pages
19
Pages from-to
9026
UT code for WoS article
000597481100001
EID of the result in the Scopus database
2-s2.0-85096678409